Justin Leong, Chief Product Officer of ResMed Inc, filed a Form 4 on November 20, 2026, disclosing the acquisition of 10,314 shares of ResMed common stock at no cost following certification that performance metrics were met on November 19, 2026.
Key Highlights
- Reporting person: Justin Leong, Chief Product Officer of ResMed Inc (NYSE:RMD)
- Transaction date: November 19, 2026, the date the shares were earned
- Shares acquired: 10,314 shares of ResMed common stock, acquired at a price of $0
- Transaction code: A (acquisition), reflecting a grant settlement rather than an open-market purchase
- Original grant date: Performance-based restricted stock units were originally granted on November 16, 2023
- Resulting ownership: 10,314 shares of ResMed common stock held directly following the transaction
ResMed Performance RSU Grant to Chief Product Officer Certified as Earned
According to the filing, Justin Leong, serving as Chief Product Officer of ResMed Inc, received 10,314 shares of ResMed common stock on November 19, 2026, at a price of $0 per share. The acquisition reflects the settlement of performance-based restricted stock units originally granted on November 16, 2023. The filing states that the shares were earned on November 19, 2026, "when the compensation and leadership development committee certified that the performance metrics were met for this portion of the grant."
The transaction is recorded in Table I of the Form 4 as a non-derivative security acquisition coded "A," indicating an award or grant rather than an open-market purchase. Following the reported transaction, the filing discloses that Leong directly beneficially owns 10,314 shares of ResMed common stock. No derivative securities were reported in Table II of the filing.
The Form 4 was filed with the SEC on November 20, 2026, one day after the transaction date. The filing was made by one reporting person and is not an amendment to a prior filing. ResMed Inc trades on the NYSE under the ticker symbol RMD.
What Was Disclosed
Justin Leong, Chief Product Officer of ResMed Inc (NYSE:RMD), reported the acquisition of 10,314 shares of common stock at $0 on November 19, 2026, upon committee certification that performance metrics were met for a November 16, 2023 performance-based RSU grant.





Please wait processing your request...